Drug
RP L201
RP L201: highest development phase Phase 1/2, developed by Rocket Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Rocket Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| RP-L201 NCT03812263 | Phase 1/2 | Leukocyte Adhesion Defect - Type I |
| RP-L201 NCT03825783 | Phase 1 | Leukocyte Adhesion Defect - Type I |
Latest
No recent events.
Follow RP L201 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.